These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 12006538)
1. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Buller RE; Shahin MS; Geisler JP; Zogg M; De Young BR; Davis CS Clin Cancer Res; 2002 May; 8(5):1196-202. PubMed ID: 12006538 [TBL] [Abstract][Full Text] [Related]
2. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330 [TBL] [Abstract][Full Text] [Related]
3. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065 [TBL] [Abstract][Full Text] [Related]
4. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ; J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670 [TBL] [Abstract][Full Text] [Related]
5. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. Rubin SC; Benjamin I; Behbakht K; Takahashi H; Morgan MA; LiVolsi VA; Berchuck A; Muto MG; Garber JE; Weber BL; Lynch HT; Boyd J N Engl J Med; 1996 Nov; 335(19):1413-6. PubMed ID: 8875917 [TBL] [Abstract][Full Text] [Related]
7. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers. Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943 [TBL] [Abstract][Full Text] [Related]
8. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636 [TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP). Geisler JP; Hatterman-Zogg MA; Rathe JA; Lallas TA; Kirby P; Buller RE Hum Mutat; 2001 Oct; 18(4):337-44. PubMed ID: 11668617 [TBL] [Abstract][Full Text] [Related]
10. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Liu Z; Wang LE; Wang L; Lu KH; Mills GB; Bondy ML; Wei Q Clin Cancer Res; 2005 Jul; 11(13):4968-76. PubMed ID: 16000597 [TBL] [Abstract][Full Text] [Related]
11. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Goodheart MJ; Ritchie JM; Rose SL; Fruehauf JP; De Young BR; Buller RE Clin Cancer Res; 2005 May; 11(10):3733-42. PubMed ID: 15897570 [TBL] [Abstract][Full Text] [Related]
12. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Goldberg I; Davidson B; Reich R; Gotlieb WH; Ben-Baruch G; Bryne M; Berner A; Nesland JM; Kopolovic J Clin Cancer Res; 2001 Dec; 7(12):4073-9. PubMed ID: 11751504 [TBL] [Abstract][Full Text] [Related]
13. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Chan KY; Ozçelik H; Cheung AN; Ngan HY; Khoo US Cancer Res; 2002 Jul; 62(14):4151-6. PubMed ID: 12124354 [TBL] [Abstract][Full Text] [Related]
15. Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families. Kim TJ; Lee KM; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG Oncol Rep; 2006 Mar; 15(3):565-9. PubMed ID: 16465413 [TBL] [Abstract][Full Text] [Related]
16. Survival of BRCA1 negative ovarian cancer patients based on family history. Chu CS; Morgan MA; Randall TC; Bandera CA; Rubin SC Gynecol Oncol; 2001 Oct; 83(1):109-14. PubMed ID: 11585421 [TBL] [Abstract][Full Text] [Related]
17. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Kang HC; Kim IJ; Park JH; Kwon HJ; Won YJ; Heo SC; Lee SY; Kim KH; Shin Y; Noh DY; Yang DH; Choe KJ; Lee BH; King SB; Park JG Hum Mutat; 2002 Sep; 20(3):235. PubMed ID: 12204006 [TBL] [Abstract][Full Text] [Related]
18. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504 [TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252 [TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]